glucagon has been researched along with bupropion in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (bupropion) | Trials (bupropion) | Recent Studies (post-2010) (bupropion) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 3,392 | 755 | 1,329 |
| Protein | Taxonomy | glucagon (IC50) | bupropion (IC50) |
|---|---|---|---|
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | 5.2693 | |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | 5.2693 | |
| Integrin alpha-5 | Homo sapiens (human) | 1.8 | |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | 5.2693 | |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | 0.9373 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.2003 | |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | 1.2028 | |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | 1.367 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1.9983 | |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | 7.9 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | 0.0135 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.0848 | |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | 5.2693 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K | 1 |
1 other study(ies) available for glucagon and bupropion
| Article | Year |
|---|---|
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss | 2023 |